Tandem shares spike

Piper Sandler upgraded Tandem Diabetes Care to Overweight on March 17, 2026 and raised its price target to $33 from $21 in a note that immediately lifted the stock. (benzinga.com) The firm explicitly pointed to a shift to pharmacy distribution and international expansion as drivers, estimating roughly $15 million of incremental U.S. pharmacy revenue in 2026 and another $33 million the following year. (marketdash.com) Investors had already reacted to fundamental beats: Tandem reported fourth‑quarter 2025 revenue of about $290.4 million on Feb. 19, 2026, topping Street estimates. (financialcontent.com) That Q4 print produced a separate, earlier rally — shares jumped roughly 30% in intraday trading after the results were released. (stockstory.org) Tandem also announced expanded device connectivity in early March, making the Tandem Mobi app compatible with Android smartphones on March 4, 2026, a commercialization step analysts flagged alongside the planned tubeless Mobi launch. (investor.tandemdiabetes.com) Despite the recent spikes, the stock has traded around the low‑$20s this week versus a 52‑week high near $28.26 in February 2026, leaving the new $33 target implying material upside from current levels. (google.com)